DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
Tirzepatide (Zepbound)
brandedFDA-approved for chronic weight management
Est. Cost
$299-$449/mo
/month
Tirzepatide, marketed as Zepbound for weight management, is a first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated what may be the most significant weight loss results of any approved medication to date. By activating two incretin hormone pathways instead of one, tirzepatide appears to offer enhanced appetite suppression and metabolic benefits compared to single-mechanism alternatives. While it carries a higher price tag than semaglutide, clinical data suggests it may deliver substantially greater weight reduction for many patients.
Dosage Format
Weekly subcutaneous injection, titrated from 2.5mg to up to 15mg over several months
Type
Branded
Best For
Patients seeking the most effective weight loss medication currently available and who can accommodate a higher price point
Key Benefit
Tirzepatide is the only dual GIP/GLP-1 receptor agonist approved for weight loss, with clinical trials suggesting it may produce 20-25% average body weight reduction — the highest of any currently available medication.
Where to Get Tirzepatide (Zepbound)
Compare providers offering tirzepatide (zepbound) — ranked by our editorial team
Ro
Branded Zepbound available with provider consultations; pricing varies by dosage tier
$299-$449/mo
/month
Calibrate
Includes Calibrate's metabolic health program with 1-on-1 coaching alongside medication
$349-$449/mo
/month
How Tirzepatide (Zepbound) Works
Tirzepatide is unique because it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual mechanism may amplify the appetite-reducing and metabolic effects beyond what single-target GLP-1 medications can achieve alone. Like other GLP-1 drugs, it appears to slow gastric emptying and reduce hunger signals in the brain. The addition of GIP receptor activation is thought to further enhance fat metabolism and improve the body's insulin sensitivity, which may contribute to the greater weight loss observed in clinical studies.
Side Effects
Common
- • Nausea (most common during dose escalation)
- • Diarrhea
- • Vomiting
- • Constipation
- • Abdominal pain
- • Decreased appetite
- • Injection site reactions
Serious (Rare)
- • Pancreatitis (rare)
- • Gallbladder problems including gallstones
- • Hypoglycemia (especially when combined with insulin or sulfonylureas)
- • Kidney injury from dehydration
- • Thyroid C-cell tumors (observed in animal studies; significance in humans is not established)
- • Severe allergic reactions including anaphylaxis
Who Is Eligible
Tirzepatide is generally prescribed for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition. It may be particularly suitable for patients who have not achieved desired results with single-mechanism GLP-1 medications. As with other medications in this class, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.